PreSENTIA hereditary cancer test panels can detect numerous inherited genetic changes (mutations) that could cause cancer in the future.

PreSENTIA offers an extensive portfolio of 19 hereditary cancer test panels. Each panel focuses on a set of genes that determine someone’s chances of developing a specific cancer in the future. The genetic changes in the genes that could cause cancer are inherited from parents to their children, and are present from birth. Knowing that a person carries one of these genetic mutations can help them take preventative measures and plan a more informed clinical management. As a result, early detection of cancer can be achieved – which increases the chances of successful treatment – or prevention.

WHAT IS CANCER?

Cancer is the rapid and uncontrollable growth of abnormal cells. It is the second leading cause of death, responsible for 1 out of 6 deaths globally. World Health Organization (WHO) recommends that cancer mortality can be significantly reduced by early detection and proper clinical management of cancers.

HOW DOES CANCER DEVELOP?

Cancer develops after certain genes that are responsible for keeping our body healthy undergo changes that cause them to become ‘faulty’. A cancer can be:

SPORADIC: Mutations in the genes causing cancer accumulate over time due to risk factors like tobacco, viruses (such as HPV), and environmental factors. These mutations cannot be inherited.

HEREDITARY: These mutations exist from birth. They run in families and can be passed down from parents to their children.

Inherited genetic mutations make up for 5-10% of all cancers.

WHAT SHOULD I ASK MY DOCTOR?

What are germline mutations?

Germline mutations are changes in the DNA that are inherited from parents to their children. These changes are present from birth in all the cells in the body. People with germline mutations in a cancer gene have a higher chance of developing cancer in their lifetime. If cancer develops due to a germline mutation, it is called hereditary cancer.

What is a hereditary screening test?

A hereditary screening test checks if an individual has an inherited gene mutation in a gene with high cancer susceptibility.

hereditary cancer family mutation possibilities

If you or a family member were diagnosed with hereditary cancer, or a genetic change that is linked to cancer, there's a high chance other members of your family carry the genetic change as well. Each individual could be affected by cancer at different age, with wide range of severity, and by different cancer types.

WHO IS THIS TEST FOR?

Identifying the genetic change that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning, avoiding risk factors and informing family members of their risk.

According to genetic testing guidelines* for cancer, people who might benefit from genetic testing are those that have:

  • Family members with cancer in the same side of the family
  • Multiple cancers in the same family member
  • Family members with early cancer onset
  • Family members with rare cancer types
  • A family member that has been diagnosed with a genetic mutation that has cancer susceptibility
  • Personal or family history of a hereditary cancer syndrome

Your healthcare provider will also take into account your medical family history, ethnicity and any physical findings present linked to cancer before recommending PreSENTIA to you.

* Data adapted from: American Cancer Society, National Cancer Institute, American Society of Clinical Oncology and American College of Obstetricians and Gynecologists.

HOW DOES PreSENTIA HELP ME?

PreSENTIA panels test for numerous genetic changes that are responsible for causing hereditary cancers. If you want to know more about your cancer risks, or if you have been already diagnosed with cancer and you want to know whether your cancer is hereditary, PreSENTIA can help.

  • Targeted cancer monitoring – recommended screening tests at key time intervals to detect cancer early, when treatment is more beneficial
  • Prevention of cancer by prophylactic measures
  • Actionable information for family members that might carry the same gene
  • Improved classification of the disease for better clinical management
  • Drug therapy (chemoprevention)

WHY CHOOSE THE PreSENTIA TEST?

  • Assesses clinically important mutations
  • Ability to select the best panel for you
  • Reliable technology
  • Short turn-around time
  • Safe and easy to perform

WHAT ARE ‘HEREDITARY CANCER SYNDROMES’?

Hereditary cancer syndromes are also known as cancer predisposing syndromes, as patients with these syndromes have an elevated risk of developing specific cancers in the future. These conditions occur when genes with critical roles in keeping our body healthy are mutated, causing a variety of symptoms and potentially affecting the quality of life. They can be inherited from one generation to the other.

Hereditary cancer syndromes characteristics

  • Multiple cancer types
  • Repeated cancers
  • Young age of cancer onset

If you have cancer in your family history and want to know about your own risk, PreSENTIA can help. By identifying the mutated genes that could cause hereditary cancer syndromes, PreSENTIA can provide information that could help in clinical management. If you have been diagnosed with cancer and have any of the above characteristics, you might also have a hereditary cancer syndrome. Identifying this can help reveal how and why your cancer was caused.

HOW ACCURATE IS IT?

TARGETED TECHNOLOGY

By focusing only on the genetic changes tested, PreSENTIA is accurate and precise.

HIGH READ DEPTH

PreSENTIA analyzes the locations of the genetic changes hundreds of times, making the test results more sensitive and reliable.

WHAT DOES IT TEST FOR?

HEREDITARY CANCER PANELS

  • BREAST & GYNECOLO­GICAL

    26

    HEREDITARY BREAST/GYNECOLOGICAL CANCER PANEL

    Description

    Hereditary Breast/Gynecological cancer panel tests for numerous germline mutations that could cause Breast, Ovarian or Endometrial cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for breast/gynaecological cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member with multiple cancers
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • Personal history of previous malignancies

    No of Genes Tested

    26

    No of related hereditary cancer syndromes

    12

    Genes Tested

    ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RAD50, RAD51C, RAD51D, SMARCA4, STK11, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • DICER 1 syndrome (DICER1)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)
    • Polymerase proofreading associated syndrome (POLD1, POLE)
    • PTEN hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    BARD1, BRIP, MRE11, NBN, PALB2, RAD50, RAD51C, RAD51D, SMARCA4

  • BREAST / GYN GUIDELINES - BASED

    19

    HEREDITARY BREAST/GYNECOLOGICAL GUIDELINES-BASED CANCER PANEL

    Description

    Hereditary Breast/Gynecological cancer guidelines-based panel tests for numerous germline mutations that could cause Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    19

    No of related hereditary cancer syndromes

    9

    Genes Tested

    ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, STK11

    Disorders associated with this panel:

    • Ataxia telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Peutz-Jeghers syndrome (STK11)
    • PTEN Hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    BARD1, BRIP, NBN, PALB2, RAD51C, RAD51D

  • BREAST
    HIGH-RISK

    7

    HEREDITARY BREAST HIGH-RISK CANCER PANEL

    Description

    Hereditary Breast High-Risk cancer panel tests for numerous germline mutations that are associated with a high risk for developing Breast, Ovarian, Endometrial or associated cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    7

    No of related hereditary cancer syndromes

    5

    Genes Tested

    BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53

    Disorders associated with this panel:

    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Li-Fraumeni syndrome (TP53)
    • Peutz-Jeughers syndrome (STK11)
    • PTEN hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    PALB2

  • BRCA1 / BRCA2

    2

    HEREDITARY BRCA1 / BRCA2 CANCER PANEL

    Description

    Hereditary BRCA1/BRCA2 cancer panel tests for germline mutations in the BRCA1 and BRCA2 genes that could cause specific cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers caused by mutations in the BRCA1/BRCA2 genes are those that have:

    • Several family members with cancer in the same side of the family
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    2

    No of related hereditary cancer syndromes

    1

    Genes Tested

    BRCA1, BRCA2

    Disorders associated with this panel:

    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)

  • COLORECTAL

    17

    HEREDITARY COLORECTAL CANCER PANEL

    Description

    Hereditary Colorectal cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • Personal history of previous malignancies

    No of Genes Tested

    17

    No of related hereditary cancer syndromes

    12

    Genes Tested

    APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53

    Disorders associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • PTEN Hamartoma syndrome (PTEN)
    • Peutz-Jeghers syndrome (STK11)
    • Hereditary diffuse gastric syndrome (CDH1)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
    • Polymerase Proofreading Associated syndrome (POLD1, POLE)
    • Hereditary mixed polyposis syndrome (GREM1)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A)
    • Constitutional Mismatch Repair syndrome (MSH2, MSH6, MLH1, PMS2)

  • COLORECTAL
    HIGH-RISK

    10

    HEREDITARY COLORECTAL HIGH-RISK CANCER PANEL

    Description

    Hereditary Colorectal High-Risk cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    10

    No of related hereditary cancer syndromes

    6

    Genes Tested

    APC, BMPR1A, EPCAM, MLH1, MSH2, MSH6, MUTYH, PMS2, SMAD4, STK11

    Disorders associated with this panel:

    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)

  • COLORECTAL
    NON-POLYPOSIS

    5

    HEREDITARY COLORECTAL NON-POLYPOSIS CANCER PANEL

    Description

    Hereditary Colorectal Non-Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary colorectal non-polyposis cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    5

    No of related hereditary cancer syndromes

    2

    Genes Tested

    EPCAM, MLH1, MSH2, MSH6, PMS2

    Disorders associated with this panel:

    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)

  • COLORECTAL POLYPOSIS SYNDROME

    7

    HEREDITARY COLORECTAL POLYPOSIS CANCER PANEL

    Description

    Hereditary Colorectal Polyposis cancer panel tests for numerous germline mutations that could cause colorectal cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary polyposis colorectal cancers are those that have:

    • At least 1 first-degree family member with colorectal cancer
    • Personal or family history of colorectal polyps or colorectal cancer
    • Personal history of a confirmed or suspected hereditary colorectal cancer syndrome
    • Family members diagnosed with cancer at a young age
    • Family members diagnosed with rare forms of cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    7

    No of related hereditary cancer syndromes

    5

    Genes Tested

    APC, BMPR1A, MUTYH, POLD1, POLE, SMAD4,STK11

    Disorders associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)
    • Polymerase proofreading associated syndrome (POLD1, POLE)

  • MYELODYSPLASTIC SYNDROME/LEUKEMIA

    24

    HEREDITARY MYELODYSPLASTIC SYNDROME / LEUKEMIA CANCER PANEL

    Description

    Hereditary Myelodysplastic syndrome / Leukemia cancer panel tests for numerous germline mutations that could cause blood cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary myelodysplastic syndromes or leukemias are those that have:

    • Family history of a hereditary cancer syndrome associated with leukemia
    • Personal history of a hereditary cancer syndrome associated with leukemia
    • An identical twin who developed leukemia in the first year of life
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    24

    No of related hereditary cancer syndromes

    6

    Genes Tested

    ATM, BRCA1, BRCA2, BRIP1, EPCAM, ERCC4, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, MLH1, MSH2, MSH6, PALB2, PMS2, RAD51C, SLX4, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
    • Hereditary breast & ovarian syndrome (BRCA1 & BRCA2)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)

  • GASTRIC

    14

    HEREDITARY GASTRIC CANCER PANEL

    Description

    Hereditary Gastric cancer panel tests for numerous inherited germline mutations that could cause gastric (stomach) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for gastric cancers are those that have:

    • Several family members in the same side of the family with gastric cancer
    • Personal or family history of a hereditary cancer syndrome linked to gastric cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    14

    No of related hereditary cancer syndromes

    8

    Genes Tested

    APC, BMPR1A, CDH1, EPCAM, MLH1, MSH2, MSH6, PMS2, SDHB, SDHC, SDHD, SMAD4, STK11, TP53

    Disorders associated with this panel:

    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Hereditary Paraganglioma-Pheochromocytoma syndrome (SDHB, SDHC, SDHD)
    • Juvenile Polyposis syndrome (SMAD4, BMPR1A)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Peutz-Jeghers syndrome (STK11)

  • PROSTATE

    15

    HEREDITARY PROSTATE CANCER PANEL

    Description

    Hereditary Prostate cancer panel tests for numerous germline mutations that could cause prostate cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary prostate cancers are those that have:

    • Several first-degree family members with prostate cancer
    • Family members diagnosed with prostate cancer at young age
    • Family members diagnosed with other cancer types, including breast, ovarian and pancreatic
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    15

    No of related hereditary cancer syndromes

    6

    Genes Tested

    ATM, BRCA1, BRCA2, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM)
    • PTEN hamartoma syndrome (PTEN)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    HOXB13, NBN, PALB2, RAD51D

  • PANCREATIC

    17

    HEREDITARY PANCREATIC CANCER PANEL

    Description

    Hereditary Pancreatic cancer panel tests for numerous germline mutations that could cause pancreatic cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for pancreatic cancers are those that have:

    • Several family members in the same side of the family with pancreatic cancer
    • First-degree relative who developed pancreatic cancer before the age of 50
    • Personal or family history of a hereditary cancer syndrome linked to pancreatic cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    17

    No of related hereditary cancer syndromes

    10

    Genes Tested

    APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), EPCAM, MEN1, MLH1, MSH2, MSH6, PALB2, PMS2, SMAD4, STK11, TP53

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Multiple endocrine neoplasia type 1 (MEN1)
    • Peutz-Jeghers syndrome (STK11)

  • RENAL

    13

    HEREDITARY RENAL CANCER PANEL

    Description

    Hereditary Renal cancer panel tests for numerous germline mutations that could cause renal (kidney) cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary renal cancers are those that have:

    • Family members that have had renal cancer, especially at a young age
    • Family members with renal cancer in both kidneys
    • Family members diagnosed with a hereditary cancer syndrome associated with renal cancer
    • Personal history of a hereditary cancer syndrome associated with renal cancer
    • Multiple cancers in the same family member
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    13

    No of related hereditary cancer syndromes

    7

    Genes Tested

    BAP1, EPCAM, MLH1, MSH2, MSH6, PMS2, PTEN, SDHAF2, SDHB, SDHC, SDHD, TP53, VHL

    Disorders associated with this panel:

    • BAP1 mutation associated disease (BAP1)
    • Constitutional mismatch repair syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHC, SDHD)
    • Li-Fraumeni syndrome (TP53)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • PTEN hamartoma syndrome (PTEN)
    • Von-Hippel Lindau syndrome (VHL)

  • SKIN (XP-ASSOCIATED)

    9

    HEREDITARY SKIN (XP-ASSOCIATED) CANCER PANEL

    Description

    Hereditary Xeroderma Pigmentosum-related cancer panel tests for numerous germline mutations that could cause skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for Xeroderma Pigmentosum-related skin cancers are those that have:

    • Family or personal history of a hereditary cancer syndrome associated with skin cancers
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    9

    No of related hereditary cancer syndromes

    1

    Genes Tested

    DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC

    Disorders associated with this panel:

    • Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)

  • FAMILIAL MELANOMA

    7

    HEREDITARY FAMILIAL MELANOMA CANCER PANEL

    Description

    Hereditary Familial Melanoma cancer panel tests for numerous germline mutations that could cause familial melanoma skin cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary melanoma cancers are those that have:

    • At least two first-degree family member who have had metastatic melanoma
    • At least one family member has had multiple melanomas
    • Family or personal history of a hereditary cancer syndrome associated with melanoma
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    7

    No of related hereditary cancer syndromes

    5

    Genes Tested

    BAP1, BRCA2, CDK4, CDKN2A (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), PTEN, RB1, TP53

    Disorders associated with this panel:

    • BAP1 mutation associated disease (BAP1)
    • Hereditary pancreatic-melanoma syndrome (CDKN2A, CDK4)
    • Li-Fraumeni syndrome (TP53)
    • PTEN hamartoma syndrome (PTEN)
    • Retinoblastoma (RB1)

  • PARAGANGLI­OMA / PHEOCHROMOCYTOMA

    6

    HEREDITARY PARAGANGLIOMA / PHEOCHROMOCYTOMA CANCER PANEL

    Description

    Hereditary Paraganglioma / Pheochromocytoma cancer panel tests for germline mutations in numerous genes that could cause Paraganglioma or Pheochromocytoma cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for Paraganglioma or Pheochromocytoma cancers are those that have:

    • Family or personal history of a hereditary cancer syndrome associated with paraganglioma / pheochromocytoma cancers
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    6

    No of related hereditary cancer syndromes

    3

    Genes Tested

    RET, SDHAF2, SDHB, SDHC, SDHD, VHL

    Disorders associated with this panel:

    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHAF2, SDHB, SDHD, SDHC)
    • Multiple endocrine neoplasia type 2 (RET)
    • Von-Hippel Lindau syndrome (VHL)

  • PARATHYROID

    1

    HEREDITARY PARATHYROID CANCER PANEL

    Description

    Hereditary Parathyroid cancer panel tests for germline mutations in the MEN1 gene that could cause parathyroid cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for parathyroid cancers are those that have:

    • At least two first-degree family member who have had parathyroid tumors
    • A personal or family history of a hereditary cancer syndrome associated with parathyroid cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    1

    No of related hereditary cancer syndromes

    1

    Genes Tested

    MEN1

    Disorders associated with this panel:

    • Multiple endocrine neoplasia type 1 (MEN1)

  • THYROID

    1

    HEREDITARY THYROID CANCER PANEL

    Description

    Hereditary Thyroid cancer panel tests for germline mutations in the RET gene that could cause medullary thyroid cancer in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for thyroid cancers are those that have:

    • At least one first-degree family member who has had thyroid cancer
    • A personal or family history of a hereditary cancer syndrome associated with thyroid cancer
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility

    No of Genes Tested

    1

    No of related hereditary cancer syndromes

    1

    Genes Tested

    RET

    Disorders associated with this panel:

    • Multiple endocrine neoplasia type 2 (RET)

  • PAN-CANCER

    62

    HEREDITARY PAN-CANCER PANEL

    Description

    Hereditary Pan-Cancer panel tests for numerous germline mutations in a total of 62 genes that could cause several cancers in the future. Identifying germline mutations associated with cancer susceptibility empowers healthcare providers and patients, as it allows them to take better and more informed decisions.

    Who is this test for?

    According to genetic testing guidelines, people who might benefit from genetic testing for hereditary cancers are those that have:

    • Several family members in the same side of the family with cancer
    • Multiple cancers in the same family member
    • Family members with early cancer onset
    • Family members with rare cancer types
    • Family members with an unusual type of cancer (breast cancer in a male)
    • Personal or family history of a hereditary cancer syndrome
    • A family member that has been diagnosed with a germline mutation associated with cancer susceptibility
    • History of previous malignancies

    No of Genes Tested

    62

    No of related hereditary cancer syndromes

    24

    Genes Tested

    APC, ATM, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, (CDKN2Ap16(INK4A), CDKN2Ap14(ARF)), CHEK2, DDB2, DICER1, EPCAM, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, GREM1, HOXB13, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, POLH, PTEN, RAD50, RAD51C, RAD51D, RB1, RET, SDHAF2, SDHB, SDHC, SDHD, SLX4, SMAD4, SMARCA4, STK11, TP53, VHL, XPA, XPC

    Disorders associated with this panel:

    • Ataxia-telangiectasia syndrome (ATM)
    • BAP1 mutation associated disease (BAP1)
    • Constitutional mismatch repair syndrome (EPCAM, MSH2, MSH6, MLH1, PMS2)
    • DICER 1 syndrome (DICER1)
    • Familial Adenomatous Polyposis / Attenuated Familial Adenomatous Polyposis (APC)
    • Fanconi anemia syndrome (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C)
    • Hereditary breast & ovarian cancer syndrome (BRCA1, BRCA2)
    • Hereditary diffuse gastric syndrome (CDH1)
    • Hereditary mixed polyposis syndrome (GREM1)
    • Hereditary melanoma-pancreatic cancer syndrome (CDKN2A, CDK4)
    • Hereditary Paraganglioma – Pheochromocytoma syndrome (SDHD, SDHAF2, SDHC, SDHB)
    • Juvenile polyposis syndrome (SMAD4, BMPR1A)
    • Li-Fraumeni syndrome (TP53)
    • Li-Fraumeni syndrome 2 (CHEK2)
    • Lynch syndrome (EPCAM, MLH1, MSH2, MSH6, PMS2)
    • Multiple endocrine neoplasia type 1 (MEN1)
    • Multiple endocrine neoplasia type 2 (RET)
    • MUTYH-associated polyposis syndrome (MUTYH)
    • Peutz-Jeghers syndrome (STK11)
    • Polymerase proofreading associated syndrome (POLD1, POLE)
    • PTEN hamartoma syndrome (PTEN)
    • Retinoblastoma (RB1)
    • Von-Hippel Lindau syndrome (VHL)
    • Xeroderma Pigmentosum syndrome (DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA, XPC)

    The following genes are not linked with a hereditary cancer syndrome but are associated with cancer risk, and are also analyzed by this panel:

    BARD1, MRE11, RAD50, SMARCA4, HOXB13, NBN, RAD51D

  • Hereditary Cancer Syndromes
    Cancer Predisposing Syndromes & Associated Genes Associated Cancers
    Li-Fraumeni syndrome
    TP53     		Breast, Ovarian, Prostate, Pancreatic, Colorectal, Gastric, Renal, Sarcomas, Brain, Lung, Leukemia
    Li-Fraumeni syndrome 2
    CHEK2     		Breast, Sarcoma, Brain
    Hereditary breast and ovarian cancer syndrome
    BRCA1, BRCA2     		Breast, Ovarian, Prostate, Pancreatic, Melanoma, Gastric, Esophagus
    Familial adenomatous polyposis/Attenuated familial adenomatous polyposis syndrome
    APC     		Gastric, Pancreatic, Colorectal, Osteomas, Small Bowel
    MUTYH-associated polyposis syndrome
    MUTYH     		Colorectal
    Lynch syndrome
    MLH1, MSH2, MSH6, PMS2, EPCAM     		Colorectal, Endometrial, Gastric, Ovarian, Prostate, Pancreatic, Renal
    PTEN hamartoma syndrome
    PTEN     		Breast, Endometrial, Colorectal, Melanoma, Renal
    Peutz-Jeghers syndrome
    STK11     		Breast, Ovarian, Endometrial, Colorectal, Gastric, Pancreatic
    Juvenile polyposis syndrome
    SMAD4, BMPR1A     		Colorectal, Gastric, Pancreatic
    Fanconi anemia syndrome
    FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, SLX4, ERCC4, BRCA1, BRCA2, BRIP1, PALB2, RAD51C     		Leukemia, Tumors of the head & neck, Gastrointestinal
    Von-Hippel Lindau syndrome
    VHL     		Renal, Paragangliomas, Pheochromocytomas
    Retinoblastoma
    RB1     		Eye, Bone, Uveal Melanoma
    Xeroderma pigmentosum syndrome
    DDB2, ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, POLH, XPA,XPC     		Non-Melanoma & Melanoma
    Hereditary melanoma-pancreatic cancer syndrome
    CDKN2A, CDK4     		Melanoma, Pancreatic
    Hereditary diffuse gastric syndrome
    CDH1     		Gastric & Breast
    DICER 1 syndrome
    DICER1     		Lung, Renal, Ovarian, Thyroid
    Polymerase Proofreading Associated syndrome
    POLD1, POLE     		Colorectal & Endometrial
    Multiple Endocrine Neoplasia (MEN) syndrome type 1
    MEN1     		Parathyroid & Pancreatic
    Multiple Endocrine Neoplasia (MEN) syndrome type 2
    RET     		Thyroid & Pheochromocytoma
    BAP1 Mutation associated disease
    BAP1     		Skin, Eye, Renal, Mesothelioma
    Ataxia-telangiectasia syndrome
    ATM     		Leukemia & Lymphoma
    Hereditary-mixed polyposis syndrome
    GREM1     		Colorectal
    Constitutional mismatch repair syndrome
    MSH2, MSH6, MLH1, PMS2     		Hematologic malignancies, Brain, Gastrointestinal, Colorectal
    Hereditary Paraganglioma – Pheochromocytoma syndrome
    SDHAF2, SDHB, SDHC, SDHD     		Renal, Thyroid, Paragangliomas, Pheochromocytomas

HOW CAN I TAKE PreSENTIA?

  • CONSULT WITH YOUR HEALTHCARE PROVIDER ON WHICH PANEL IS IDEAL FOR YOU
  • YOUR DOCTOR WILL COLLECT A BUCCAL SWAB SAMPLE FROM YOU
  • THE SAMPLE WILL BE SENT TO OUR LABORATORY
  • THE SAMPLE WILL BE ANALYZED IN OUR LABORATORY
  • RESULTS WILL BE SENT TO YOUR HEALTHCARE PROVIDER WITHIN 2-3 WEEKS

FAQ

  • What are mutations?

    A mutation is a change that happens in the DNA that could possibly affect the health of an individual.

  • What is genetic testing?

    Genetic testing identifies changes in the DNA.

  • What is cancer susceptibility and cancer predisposition?

    Cancer susceptibility, or predisposition, is the likelihood of being affected by cancer in the future. This depends on an individual’s DNA. There are certain inherited, genetic changes that raise someone’s risk of developing cancer in the future. This is because these changes happen in genes that are responsible for protecting the body from disease, and when they are affected, their protective role halts.

  • What are germline mutations?

    Germline mutations are changes in the DNA that are inherited from parents to their children. These changes are present from birth in all the cells in the body. Germline mutations are different from somatic mutations, which occur when a genetic change happens in the DNA due to exposure to risk factors – after a person is born. People with germline mutations in a cancer gene have a higher chance of developing cancer in their lifetime. If cancer develops due to a germline mutation, it is called hereditary cancer.

  • What is hereditary screening?

    A hereditary screening test checks if an individual has an inherited, genetic change in a gene with high cancer susceptibility from birth. Identifying the mutation that could cause cancer in the future is useful for people with cancer in their family history, and for people suspected of having a hereditary form of cancer. This knowledge can help with better medical planning and avoiding risk factors.

  • How do I decide what is the best panel for me?

    Your healthcare provider will recommend the best panel for you after considering the types of cancers that have affected your family members, any genetic changes that have already been diagnosed in one of your family members, and any symptoms exhibited. Consult with your healthcare provider on which panel is ideal.

NIPD Genetics - Privacy Policy

General Statement

NIPD Genetics is a leading, innovative biotechnology company that designs, develops, and provides a broad spectrum of healthcare services to its customers through its expansive portfolio of molecular and clinical laboratory tests in all disciplines.

At NIPD Genetics we are committed to protecting and respecting our customer’s privacy and personal information. Personal information or personal data means any information that identifies, relates to, describes, is capable of being associated with, or could be reasonably linked, directly or indirectly, with a particular individual, such as name, identification number, location data, an online identifier or to one or more factors specific to the physical, physiological, genetic, mental, economic, cultural or social identity of that individual.

NIPD Genetics collects and processes your personal information according to the General Data Protection Regulation (EU) 2016/679 and the Cypriot law providing for the protection of natural persons with regards to the processing of personal data and for the free movement of such data (L. 125(I)/2018). The following principles lie at the heart of our approach to handling personal data:

NIPD Genetics has appointed a Data Protection Officer (DPO) who is responsible for overseeing and ensuring that personal information is collected and processed in line with these principles. The contact details of the Data Protection Officer (DPO) can be found below:

Email address: dpo@nipd.com

Postal address: 31 Neas Engomis street, 2409 Engomi, Nicosia, Cyprus

Telephone number: + 357 22266888

By accessing or using our products or services, or by transmitting information to us by email or other electronic means, you accept our policies, procedures and practices described in this Privacy Policy. If you do not agree with our policies, procedures and practices as described, you can choose not to access or use our products or services or not to transmit personal information to us.

This Privacy Policy applies to NIPD Genetics facilities, its websites www.nipd.com, www.nipdlabs.com, www.nipdlabs.com.cy and their subdomains, that link to this privacy pol icy.

PERSONAL INFORMATION COLLECTION AND PROCESSING

We collect and process several types of personal information from and about users of our websites and of our products and services, including:

Information about children

If you are under 18 years of age, do not register on our website or provide any information about yourself to us. We do not provide our products or services directly to children or proactively collect their personal information. Despite this prohibition, it is possible that we may sometimes be given information about children while handling samples from our customers in our clinical labs, or through use of our products and services by our customers and partners. If we become aware that we have inadvertently collected personal information from children under the age of 18, without parental consent, we will take the necessary steps to delete it as soon as possible in compliance with applicable laws.

LEGAL BASIS FOR PROCESSING OF YOUR PERSONAL INFORMATION

Your personal information is collected by NIPD Genetics for the following purposes:

  1. To provide you with our products and services, respond to your inquiries or fulfill your requests and otherwise manage your relationship with us. The legal basis for processing is to meet the requirements of a contract, to comply with our legal obligations and/or because we have a legitimate interest in responding to requests for information about our products and services.
  2. To communicate with you about content and product offerings, newsletters and event invitations which are relevant to your interests and in line with your preferences. The legal basis for processing is the individual’s explicit consent prior to sending the information and managing individuals preferences.
  3. To process and respond to complaints. The legal basis for processing is to meet a legal obligation.
  4. To monitor and record information relating to the use of our products and services, including our website. The legal basis for processing is our legitimate interest in order to improve our products and services and our website for individuals.

To provide our products and services, NIPD Genetics may collect, receive and process biological samples to isolate and sequence DNA. NIPD Genetics may then store resulting genetic information and use genetic information to provide our products and services. In some cases, NIPD Genetics may provide interpretations of genetic information on behalf of its customers, including healthcare providers. This is only done pursuant to a written contract or a Sample Information Form with a patient’s informed consent and is subject to applicable legal and ethical safeguards.

This sensitive information described above is collected by NIPD Genetics for the following purposes:

  1. To provide support and maintenance services to customers who use our products and services – The legal basis for processing is to meet the requirements of a contract.
  2. To provide genotyping and sequencing services and analysis for our customers, including healthcare providers. The legal basis of this processing is to meet the requirements of a contract or as allowed in the Sample Information Form with a patient’s informed consent.
  3. To conduct genotyping and sequencing services and analysis for quality control, process and product development and improvements, and optimization in our labs to reflect quality improvements and advances in our technology. The legal basis for processing is the patient’s informed consent given through the Sample Information Form.

Transfer of Data

Your information, including personal data, may be transferred to - and maintained on - computers located outside your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

NIPD Genetics will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal information will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the General Data Protection Regulation and will not sell or trade your personal information.

NIPD Genetics may disclose your personal information in the good faith that such action is necessary:

COOKIES AND OTHER TRACKING TECHNOLOGIES

Cookies are files with small amount of data which may include an anonymous unique identifiers. Cookies are sent to your browser when you visit a website and stored on your device. Tracking technologies used on the website are beacons, tags and scripts, to collect and track information and to improve and analyze our websites.

We use cookies and similar tracking technologies to track the activity on our websites and collect certain information. This includes information about the computer or device you are using, such as Internet protocol (IP) address, information about the browser type or version, the pages of our website that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our websites.

Examples of Cookies we may use:

Session Cookies. We use Session Cookies to operate our websites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the websites

Keyword cookies. To understand how visitors discover the websites.

ANALYTICS

We may use third-party Service Providers to monitor and analyze the use of our websites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

SECURITY OF DATA

We are committed to protecting the security of the information we collect, and we take reasonable physical, technical, and administrative safeguards such as data anonymization and encryption to help protect personal information from unauthorized or inappropriate access or use. It is your responsibility to protect the confidentiality of your passwords, and any other access features associated with your access or use of the website or our products and services, as well as to adhere to any applicable Terms of Use or other contract between us and you or your organization.

PERSONAL DATA RETENTION

We may retain collected information even after you remove it from the website, our Services, or our Products, to comply with applicable law, to resolve disputes, to enforce any rights in connection with the website, our Services, or our Products, and to use as provided in this Privacy Policy, the Terms of Use, or an applicable contract between us and you or your organization. How long we retain specific personal information varies depending on the purpose for its use and we may delete or retain your personal information in accordance with applicable law.

SERVICE PROVIDERS

We may employ third party companies and individuals to facilitate, maintain or operate our websites (“Service Providers”), to provide the websites on our behalf, to perform service-related services or to assist us in analyzing how our websites are used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

LINKS TO OTHER SITES

Our websites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

CHANGES TO THIS PRIVACY POLICY

This Privacy Policy may be updated from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our website, prior to the change becoming effective and update the “effective date” at the bottom of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

YOUR LEGAL RIGHTS

NIPD Genetics ensures that it can respond immediately to requests that you make for the exercise of your legal rights in accordance with data protection laws. These rights are as follows:

You also have the right to lodge a complaint at any time to the Office of the Commissioner for Personal Data Protection.

We encourage you to contact us, should you wish to practice any of your legal rights or you have any questions about this Privacy Policy, by sending an email to NIPD Genetics’ Data Protection Officer at dpo@nipd.com.

Effective date: 18/06/2021

Ok got it!